Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Bortezomib (Primary) ; Romidepsin (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 19 Apr 2018 Status changed from active, no longer recruiting to completed.
- 19 Jul 2017 Planned End Date changed from 30 Jun 2017 to 30 Apr 2018.
- 03 May 2017 Planned End Date changed from 30 Apr 2017 to 30 Jun 2017.